Drug Profile
Falciparum malaria vaccine - Swiss TPH Institute/Telormedix
Alternative Names: TMX 201 adjuvant-based Malaria vaccine - Swiss TPH Institute/TelormedixLatest Information Update: 30 Oct 2021
Price :
$50
*
At a glance
- Originator Swiss Tropical and Public Health Institute
- Developer Swiss Tropical and Public Health Institute; Telormedix
- Class Antimalarials; Parasitic vaccines
- Mechanism of Action Immunostimulants; Toll-like receptor 7 modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Falciparum malaria
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for phase-I development in Falciparum-malaria(Prevention) in Switzerland (Parenteral)
- 09 Jan 2014 Phase I development is ongoing in Switzerland